Amsterdam 2016 (IWWM-9)
Amsterdam 2016 Organizers
- MJ Kersten MD, Ph.D (U. Amsterdam)
- Monique Minnema MD, Ph.D (UMC Utrecht)
- Steven Pals MD, Ph.D (U. Amsterdam)
- Steven Treon MD, Ph.D (Dana-Farber)
- Chris Patterson - Secretariat (Dana-Farber)
The Amsterdam 2016 Scientific Committee members:
Stephen Ansell MD, PhD (USA)
Christian Buske MD, PhD (Germany)
Jorge Castillo MD (USA)
Meletios Dimopoulos MD (Greece)
Ramón García-Sanz MD, PhD (Spain)
Marie Jóse Kersten MD, PhD (Netherlands)
Douglas E Joshua AM (Australia)
Véronique Leblond MD (France)
Xavier Leleu MD, PhD (France)
Mary McMaster MD, PhD (USA)
Giampaolo Merlini MD (Italy)
Monique Minnema MD, PhD (Netherlands)
Enrica Morra MD (Italy)
Roger Owen MD, MRCP, FRCPath (UK)
S.T. Pals, MD, PhD (Netherlands)
Linda Pilarski PhD (Canada)
Steven Treon MD PhD (USA)
Click here to download the preliminary program agenda for the 9th International Workshop on WM (IWWM-9).
Click here to display the sponsors for the 9th International Workshop on WM (IWWM-9).
Choose from the following list of IWWM-9 (Amsterdam 2016) conference sessions:
Symposium on Advances in Multiple Myeloma
Session 1: Diagnostic Workup of WM
Session 2: Predisposition in WM
Session 3: Malignant Transformation in WM
Session 4: Genomic Landscape in WM
Session 6: Keynote Lectures: Myddosome Signaling: What have we learned?
Session 7: CXCR4 WHIM mutations and WM Pathogenesis
Session 8: Non-MYD88 and CXCR4 Signaling in WM
Session 9: BTK directed Therapy in WM
Session 10: Short Oral Discussion of Selected Poster Abstracts
Session 11: Novel Therapeutic approaches for WM
Session 12: Great Debate I - What should be the frontline standard for treatment of WM?
Session 12: Great Debate II - What should be the goal of therapy in 2017 for WM patients?
Session 13: Management of Specific Disease Morbidities in WM (Part 1)
Session 14: Management of Specific Disease Morbidities in WM (Part 2)
Session 15: Discussion: When should autologous transplant be offered to WM patients?
Registration is closed for this event.
Amsterdam 2016 (IWWM-9) was held at the Renaissance Hotel in Amsterdam.
Please enjoy this interactive sightseeing map of Amsterdam:
Please select the gallery to be viewed. Special thanks to Roger Brown (WMUK) and Bob Manning (Bing Ctr) for contributing to the photos.
The following slide presentations given at the Doctor-Patient Forum can be viewed by clicking the desired presentation:
About the IWMF Carl Harrington
WM Diagnostics, Symptoms, & Treatment Criteria Ramon Garcia-Sanz
Predispositions: Familial & Secondary Cancers Robert Kyle
Biomarkers & Genomic Targets: MYD88 & CXCR4 Zachary Hunter
Disease Morbidities I: PN, Bing-Neel, Renal Monique Minnema
Upfront Treatment Approaches Jorge Castillo
Relapsed Refractory Approaches MJ Kersten
Disease Morbidities II: Amyloid, IgM Related Disorders, Hyperviscosity and Cryos Josephine Vos
Self-Management: Fitness, Supplements, Diet & Fatigue Toni Dubeau
New York 2018 (IWWM-10)
New York 2018 Conference Chairs
- Jorge Castillo, MD (Dana-Farber)
- Richard Furman, MD (Cornell University)
- M. Lia Palomba, MD (Memorial Sloan Kettering)
- Steven Treon, MD, PhD (Dana-Farber)
- Chris Patterson - Secretariat (Dana-Farber)
The New York 2018 Scientific Committee members:
Ranjana Advani, MD (USA)
Jorge Castillo MD (USA)
Meletios Dimopoulos MD (Greece)
Ramón García-Sanz MD, PhD (Spain)
Zachary Hunter, PhD (USA)
Efstathios Kastritis, MD, PhD (Greece)
Marie Jóse Kersten MD, PhD (Netherlands)
Douglas E Joshua AM (Australia)
Véronique Leblond MD (France)
Giampaolo Merlini MD (Italy)
Roger Owen MD, MRCP, FRCPath (UK)
S.T. Pals, MD, PhD (Netherlands)
Marvin Stone, MD (USA)
Marzia Varretoni, MD (Italy)
Choose from the following list of New York 2018 (IWWM-10) conference sessions:
Session 1: Genomics in the Diagnosis and Management of WM
Session 2: Predisposition to WM
Session 3: Disease Presentation in WM
Session 4: Genomic Landscape of WM
Session 5: Mechanisms of Tumor Growth and Survival in WM
Session 6: Oral Presentations of Selected Abstracts I
Session 7: Rituximab-based Therapy
Session 8: Clinical Trial Updates in WM: Proteasome Inhibitors
Session 9: Clinical Trials Updates in WM: Ibrutinib
Session 10: Clinical Trials Updates in WM: Novel Agents and Trials in Progress
Session 11: Ibrutinib Resistance in WM
Session 12: Oral Presentations of Selected Abstracts II
Session 13: Specialized Treatment Approaches to WM
Session 15: Associated and Secondary Malignancy Risks in WM Patients
Registration for this meeting is now closed.
New York 2018 (IWWM-10) was held at the New York Marriott Downtown in New York City.
Please select the gallery to be viewed.